2619 completed. 2619 Phase 2, 520 Phase 1, 82 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2619 | Completed 2619 |
| Phase 1 | 520 | Completed 520 |
| Phase 3 | 82 | Completed 82 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients the COMBO Endoscopy Oropharyngeal Airway - Hypoxia, Esophageal Cancer | Phase 2 | Completed | Zhejiang University | 107 | 2025-02-04 | 2025-05-21 |
| Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation - Hypoxia, Esophageal Cancer | Phase 2 | Completed | Zhejiang University | 50 | 2025-02-04 | 2025-06-25 |
| Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure Endoscopic Clipping, ICG injection - Colon Cancer | Phase 2 | Completed | Seoul National University Hospital | 110 | 2024-12-10 | 2026-08-05 |
| A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer neoadjuvant SCRT followed by Sintilimab plus CAPOX - Rectal Cancer | Phase 2 | Completed | Sun Yat-sen University | 52 | 2024-12-01 | 2026-03-04 |
| Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin, Tegodor - Pancreatic Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Ruijin Hospital | 40 | 2024-08-23 | 2026-03-24 |
| Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study Interleukin-2, Radiotherapy, Tislelizumab - Rectal Cancer | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 130 | 2024-08-18 | 2026-06-24 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Cetuximab, Encorafenib - Colorectal Cancer | Phase 2 | Completed | Gruppo Oncologico del Nord-Ovest | 16 | 2024-07-23 | 2026-10-28 |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Trishula Therapeutics, Inc. | 194 | 2024-03-25 | 2026-05-13 |
| Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption Energy drink - Colorectal Cancer | Phase 2 | Completed | University of Florida | 76 | 2024-02-28 | 2025-05-06 |
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer 68Ga-FAPi-46 - Gastric Cancer, Gastro Esophageal Junctional Cancer | Phase 2 | Completed | Aalborg University Hospital | 20 | 2024-02-15 | 2025-12-30 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab - Hepatocellular Carcinoma, Radiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-01-25 | 2026-04-17 |
| Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma T-DXd, Nivolumab, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Center Hospital East | 30 | 2023-12-20 | 2026-04-14 |
| First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients IL15-transpresenting WT1-targeted Dendritic Cell Vaccine - Esophageal Cancer, Pancreas Cancer | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 10 | 2023-12-06 | 2026-06-08 |
| A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma LBL-007, Tislelizumab, Chemotherapy Doublet - Esophageal Cancer, Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | BeiGene | 118 | 2023-11-08 | 2026-05-28 |
| Avatrombopag vs. Placebo for CIT in GI Malignancies Avatrombopag, Matching Placebo - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 2 | Completed | Hanny Al-Samkari, MD | 49 | 2023-11-01 | 2026-08-31 |
| Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail Sintilimab with Interleukin-2+CAPOX - Locally Advanced Rectal Adenocarcinoma | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 33 | 2023-10-21 | 2025-01-21 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors nab-sirolimus - Neuroendocrine Tumors, NET | Phase 2 | Completed | Aadi Bioscience, Inc. | 12 | 2023-10-20 | 2026-08-25 |
| Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions Tislelizumab - Hepatocellular Carcinoma by BCLC Stage | Phase 2 | Completed | UNICANCER | 50 | 2023-10-12 | 2025-11-17 |
Showing 20 of 2619. Sign in to see all of them.
Colorectal Neoplasms (735) · Pancreatic Neoplasms (525) · Stomach Neoplasms (371) · Carcinoma, Hepatocellular (352) · Rectal Neoplasms (314) · Colonic Neoplasms (290) · Esophageal Neoplasms (250) · Neoplasm Metastasis (173) · Liver Neoplasms (162) · Neoplasms (152) · Esophageal Squamous Cell Carcinoma (87) · Biliary Tract Neoplasms (83) · Gastrointestinal Stromal Tumors (81) · Adenocarcinoma Of Esophagus (80) · Ovarian Neoplasms (78)
Digestive System Diseases (2603) · Neoplasms by Site (2546) · Neoplasms (2467) · Gastrointestinal Diseases (1614) · Gastrointestinal Neoplasms (1562) · Intestinal Diseases (978) · Intestinal Neoplasms (970) · Rectal Diseases (902) · Colonic Diseases (849) · Neoplasms by Histologic Type (790) · Neoplasms, Glandular and Epithelial (689) · Endocrine System Diseases (631) · Endocrine Gland Neoplasms (630) · Carcinoma (619)
Oxaliplatin (357) · Fluorouracil (347) · Gemcitabine (285) · Capecitabine (259) · Leucovorin (239) · Irinotecan (236) · Bevacizumab (199) · Cisplatin (197) · Cetuximab (143) · Radiotherapy (143) · Docetaxel (106) · pembrolizumab (85) · Paclitaxel (84) · Sorafenib (82) · Nivolumab (73)
National Cancer Institute (NCI) (158) · Memorial Sloan Kettering Cancer Center (57) · M.D. Anderson Cancer Center (51) · Eli Lilly and Company (45) · Alliance for Clinical Trials in Oncology (39) · Hoffmann-La Roche (39) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (32) · Asan Medical Center (31) · Dana-Farber Cancer Institute (31) · Novartis Pharmaceuticals (30) · Sun Yat-sen University (27) · Amgen (25) · Samsung Medical Center (23) · Federation Francophone de Cancerologie Digestive (21) · Fudan University (21)
United States (1257) · China (304) · South Korea (242) · France (222) · Germany (201) · Spain (191) · Italy (167) · Canada (162) · United Kingdom (150) · Taiwan (114) · Belgium (105) · Japan (101) · Netherlands (67) · Australia (60) · Hong Kong (49)
Steven R. Alberts, MD (10) · Salah-Eddin Al-Batran, Prof. Dr. (8) · Tim F Greten, M.D. (8) · Aminah Jatoi, MD (7) · David H. Ilson, MD, PhD (7) · Hedy L. Kindler, MD (7)
PMID 36852452, PMID 19192962, PMID 22473314, PMID 28712102, PMID 37934000, PMID 38592721, PMID 39863139, PMID 15496622, PMID 16908937, PMID 20838998, PMID 22070868, PMID 22646630, PMID 23393196, PMID 23493136, PMID 23547075, PMID 24146220, PMID 26049686, PMID 28103904, PMID 28742685, PMID 29929491, PMID 30420614, PMID 31803504, PMID 32698790, PMID 32816630, PMID 33087333, PMID 33198671, PMID 33337539, PMID 33416261, PMID 33856599, PMID 34213592, PMID 34289971, PMID 35100697, PMID 35623069, PMID 35771259, PMID 37119510, PMID 37496366, PMID 39437804, PMID 41044356, PMID 41811823, PMID 10029607, PMID 10207464, PMID 10235156, PMID 10493478, PMID 10517918, PMID 10573522, PMID 10811496, PMID 10811995, PMID 10924610, PMID 10984283, PMID 11208820
2009 (24), 2017 (24), 2016 (18), U10CA032102 (18), 2008 (17), 2014 (17), P30CA016672 (14), 2015 (13), 2018 (12), 2019 (12), P30CA015083 (12), U10CA021115 (11), N01CM62201 (9), P30CA006973 (9), P30CA008748 (9)